The QMN Weekly Bulletin

Every day brings new ways to use social media. New apps, new trends, and new challenges. Your company can’t afford not to use this marketing channel, but how do you balance the presentation of risks versus benefits? What’s considered off-label marketing in this medium?

Even the FDA isn’t sure what to do. Yet in response to a recent citizen petition, the agency is seeking public input on how it should regulate scientific exchanges on off-label uses for medical products. Companies have until March 27 to comment.

A recent guidance offers some clarity. It urges drugmakers who get unsolicited off-label questions via social media to take the conversation off-line. But many questions remain and who knows when the FDA will publish its other promised social media guidance. 

FDAnews has the solution here and now: Social Media Strategies for Drug and Device Companies is a report that answers your questions about how the FDA is applying its regulations to social media marketing and advertising. You’ll read about real cases and learn how to troubleshoot risks and challenges most effectively.

In addition to parsing out the latest guidance for off-label communications, this report will help keep your pharma marketers up to date with current requirements and give you insider guidance on how to get your message out with this ever-changing technology.

Don’t let the next wave of social media changes drown you, click here to order your copy of Social Media Strategies for Drug and Device Companies today.